Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

Published on May 7, 2025
The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.
Continue reading on website
Other news

CIME 2025: Exploring pharmacological options for presbyopia correction with Selina McGee, OD, FAAO

May 7, 2025
Selina McGee, OD, FAAO, emphasized that today’s approach to presbyopia correction must move beyond traditional methods like spectacles and contact lenses.

Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME

May 7, 2025
The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.